



# Increasing Access to NCD medicines in the Caribbean 22-23 February 2017

### Room B, PAHO Headquarters 525 23<sup>rd</sup> St NW Washington, DC USA

#### **AGENDA**

#### Context:

Noncommunicable Diseases (NCDs) — including cardiovascular diseases, cancer, chronic respiratory diseases and diabetes — are the leading cause of death in the Caribbean. Prevention of NCDs is important, however, investing in better NCD management is a key component of the NCD response. Management of NCDs includes the screening, detection and treatment of NCDs as well as palliative care. Such interventions are essential for achieving the global target of a 25% relative reduction in premature mortality from NCDs.

One of the noncommunicable disease (NCD) global voluntary targets is "an 80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major NCDs in both public and private facilities". However, in reviewing the results of the progress with the NCD targets, a significant gap is noted in achieving this target. Therefore, the Unit of Noncommunicable Diseases (NMH/ND) of the Department of Noncommunicable Diseases and Mental Health (NMH), and the Unit of Medicines and Health Technologies (HSS/MT) of the Department of Health Systems and Services (HSS) will convene the national NCD program managers and those responsible for drug policy/procurement in the Caribbean, to discuss how best to improve access to quality NCD medicines in the region.

#### **Purpose:**

- 1. To review and discuss the situation regarding the global, regional and national NCD commitments, specifically related to NCD medicines.
- 2. To discuss the barriers and solutions to improve quality, availability and equitable access to NCD medicines, including opioids, in the Caribbean.
- 3. To stimulate the use of the PAHO Strategic Fund for NCD drug procurement in the Caribbean.

#### **Expected Result:**

- 1. Improved awareness and understanding of the gaps and barriers in access to NCD medicines.
- 2. Increased understanding of how the PAHO Strategic Fund can be utilized to improve access to NCD medicines.
- 3. A plan on how PAHO and Member States can work more intensely together to improve the quality, availability and equitable access to NCD medicines, including opioids, in the Caribbean.

## Wednesday, 22 February, 2017

8:30am	Participant registration
9:00am	Welcome and Opening Remarks
	Dr. Anselm Hennis, Department of Noncommunicable Diseases and Mental Health, PAHO
	Dr. Analia Porras, Medicines and Technologies Unit, PAHO
9:30am	SESSION 1: NCD SITUATION AND COMMITMENTS FOR NCD MANAGEMENT  Moderator: Silvana Luciani
9:30am	Regional NCD Plan of Action and Commitments for NCD Management  Silvana Luciani, Noncommunicable Diseases Unit, PAHO
	Questions and answers
9:50am	Essential Medicines for NCD Management  Dr. Anselm Hennis, PAHO
	Questions and answers
10:10am	Improving access to NCD medicines in the OECS  Dr. Francis Burnett, OECS Pharmaceutical Procurement Services
	Questions and answers
10:30am	Coffee break
10:45am	SESSION 2: PAHO STRATEGIC FUND  Moderator: Analia Porras
10:45am	Overview of the PAHO Strategic Fund and its Benefits  Analia Porras, Medicines and Technologies Unit, PAHO
	Questions and answers
11:15am	Operations and Procedures of the PAHO Strategic Fund  Manuel Lavayen, Medicines and Technologies Unit, PAHO
	Questions and answers
11:45am	Commentary from participating Member States on experiences and benefits of utilizing the PAHO Strategic Fund
	Discussion
12:30pm	LUNCH

2.00pm	SESSION 3: COUNTRY SITUATION ON NCD MEDICINES
	Moderator: Tomo Kanda
2:00pm	Example from Barbados: Standardized hypertension approach to improve outcomes
	Dr. Kenneth Connell, Barbados Questions and answers
	Questions and answers
2:25pm	Experiences with the Jamaica National Health Fund and NCD medicines
	Erica McIntosh, National Health Fund
	Questions and answers
2:50pm	Trinidad & Tobago: Challenges and opportunities to improve access to NCD medicines
	Andrea Goddard Grimes, Trinidad & Tobago
	Questions and answers
3:10pm	Discussion on the gaps, barriers and lessons learned to improve access to NCD medicines
3:30pm	Coffee break
3.30piii	Correct Mean
3:45pm	SESSION 3 Cont'd: COUNTRY SITUATION ON NCD MEDICINES
	Moderator: Tomo Kanda
3:45pm	Haiti: experiences with PROMESS
	Sandra Benjamin, PROMESS
	Questions and answers
4:10pm	Bahamas: experiences to improve access and quality of NCD medicines
	Dr. Marvin Smith, Bahamas
	Questions and answers
4:35 pm	Discussion on gaps, barriers and lessons learned
4.E0nm	CONCLUSIONS from the day's discussions
4:50pm	Dr. Anselm Hennis, PAHO
5.00pm	ADJOURN

## Thursday, 23 February 2017

9:00am	Review and highlights of previous day's discussion Silvana Luciani, PAHO
0.45	·
9:15am	SESSION 3 Cont'd : COUNTRY SITUATION ON NCD MEDICINES  Moderator: Mauricio Cerpa
9:15am	Belize: Challenges and suggestions on how to improve access to NCD medicines  *Dr. Francis Morey, Belize*  Questions and answers
9:40am	Guyana: Availability, access and gaps for NCD medicines  Dr. Serena Bender, Guyana  Questions and answers
10:05am	Suriname: Challenges to meet the NCD target of 80% availability of NCD medicines  *Dr. Maurreen Wijngaarde-Van Dijk, Suriname*  Questions and answers
10:30am	Coffee
11:00am	SESSION 4: COUNTRY NEEDS TO IMPROVE ACCESS AND QUALITY TO NCD MEDICINES  Moderator: Silvana Luciani  Moderated discussion to identify the barriers and needs in each country to improve access, quality, and coverage of NCD medicines, for each disease: cardiovascular diseases, cancer, diabetes, chronic respiratory diseases.
12.00pm	SESSION 5: STRATEGIES TO IMPROVE ACCESS TO NCD MEDICINES  Moderator: Analia Porras  Moderated discussion and agreement on the strategies, actions and priorities for technical cooperation to Caribbean Member States to improve access to NCD medicines.
12:30pm	LUNCH
2:00pm	SESSION 6: A PLAN TO IMPROVE ACCESS TO NCD MEDICINES IN THE CARIBBEAN  Moderator: Silvana Luciani and Analia Porras
	Development and agreement on the workplan, milestones, timelines, and technical support from PAHO to Member States, to improve access to NCD medicines.
3:30pm	Final agreements, next steps and concluding remarks Silvana Luciani and Analia Porras
4.00pm	Adjourn